01—Abstract
Summary
Summary of the 8-K filed December 11, 2003. Cited figures are marked; the original filing is the authoritative source.
The Procter & Gamble Company filed this Form 8-K on December 11, 2003 under Regulation FD to publicly reaffirm its previously announced earnings guidance for the fiscal 2003/04 second quarter (October to December 2003) and the full fiscal year.
The filing contains no new financial results or guidance changes; its purpose is to confirm existing expectations, which is a common practice for mid-quarter updates that reduce uncertainty ahead of quarter-end. Management expects the October-December quarter to mark the eighth consecutive quarter of sales growth at or above its long-term objective of 4%a to 6% growth (excluding foreign exchange). Organic volume growth is projected at 7% to 8%, against a strong prior-year base of 7% organic volume growth.
Volume gains are being led by fabric and home care, health care, and developing markets, particularly Russia and China. Total sales growth is guided to 14%b to 18%, with roughly 3% to 4% from favorable foreign exchange and 6% to 7% from acquisitions and divestitures, primarily the Wella acquisition. Price and mix are expected to be a drag of 1% to 2%.
Investors should note that the guidance is heavily influenced by acquisitions and currency rather than underlying pricing power, since price/mix is expected to be negative. The forward-looking statements caveat flags risks including competitive intensity, successful integration of Wella, the potential divestiture of the juice business, customer relationships, raw material cost increases, currency volatility, and regulatory or legal matters including product liability.
02—Key points
Key Highlights
- P&G reaffirmed previously announced earnings guidance for the fiscal 2003/04 second quarter and full fiscal year; no guidance change was disclosed.
- Expected October-December 2003 sales growth at or above the long-term objective of 4% to 6%, marking the eighth consecutive quarter meeting that target.
- Organic volume growth guided to 7% to 8%, versus a strong prior-year base of 7% organic volume growth.
- Total sales growth expected at 14% to 18%, including roughly 3% to 4% from foreign exchange and 6% to 7% from acquisitions and divestitures, primarily Wella.
- Price and mix expected to be a headwind of negative 1% to 2%, indicating reliance on volume and M&A rather than pricing.
- Volume growth led by fabric and home care, health care, and developing markets, particularly Russia and China.
- Filing references risks including Wella integration, a potential juice business divestiture, raw material cost increases, currency volatility, and product liability matters.
03—Questions
Frequently Asked Questions
Did P&G change its earnings guidance in this filing?
No. The December 11, 2003 release confirmed previously announced earnings guidance for the second quarter and fiscal year. It did not revise expectations up or down.
What sales growth does P&G expect for the October-December 2003 quarter?
Total sales growth is expected to be 14% to 18%. This includes about 3% to 4% from foreign exchange and 6% to 7% from acquisitions and divestitures, mainly Wella. Organic volume growth is projected at 7% to 8%, with price and mix a negative 1% to 2%.
How much of the expected growth comes from underlying business performance?
Organic volume growth of 7% to 8% is the main underlying driver. Price and mix are expected to subtract 1% to 2%, so pricing is not contributing positively. The bulk of the headline growth above organic volume comes from currency and acquisitions.
Which segments and markets are driving growth?
Management cited fabric and home care, health care, and developing markets, particularly Russia and China, as leading volume growth.
What risks should investors monitor?
Key risks include competitive activity in P&G's focus categories, integration of the Wella acquisition, the potential divestiture of the juice business, maintaining key customer and supply relationships, raw material cost inflation, currency and interest rate volatility, and legal or regulatory matters such as product liability.
04—Continue